GlassScriptPhysician profile
Gayle C Howard
NPI 1306872411
$13,108.20
in general payments reported to CMS, 2019-2025
20 companies · $238 in 2025
The $238 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,922 · 2020: $84.93 · 2021: $5,024 · 2022: $2,007 · 2023: $423 · 2024: $408 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $7,983.29 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $1,423.35 | 2022-2023 | Vyzulta, Miebo |
| Alcon Vision LLC | $878.42 | 2019-2025 | Clareon, Rocklatan, Rhopressa |
| Allergan, INC. | $638.03 | 2019-2021 | |
| Glaukos Corporation | $583.38 | 2020-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3, Photrexa Cross-Linking Kit |
| Ivantis, INC | $470.55 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $224.00 | 2019-2021 | |
| Sight Sciences, INC. | $150.39 | 2022 | |
| Abiomed | $141.97 | 2022 | |
| Novartis Pharmaceuticals Corporation | $136.84 | 2019 | |
| Ocular Therapeutix, INC. | $124.99 | 2019 | |
| Abbvie INC. | $115.75 | 2022-2025 | |
| Oyster Point Pharma, INC. | $66.33 | 2022-2024 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $29.46 | 2024 | Vevye |
| Tarsus Pharmaceuticals, INC. | $29.29 | 2024 | Xdemvy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $28.36 | 2021 | |
| Astellas Pharma US INC | $25.66 | 2024 | Izervay |
| Kala Pharmaceuticals, INC. | $23.22 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Rxsight INC | $15.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gayle Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.